Sanofi announced it is punting more than $9 billion to acquire Blueprint Medicines and its Ayvakit, BLU-808 and immunology ...

Sanofi (SNY) has its hands full—in the best way possible—after announcing its $9.5 billion acquisition of Blueprint Medicines. This marks the French pharma giant’s fourth major strategic acquisition ...

Byron Allen dials out, Salesforce logs in. Here are the various deal announcements of the past week plus bankruptcy updates.

The acquisition includes a rare immunology disease medicine and an advanced and early-stage immunology pipeline.

Sanofi announced that it will buy pharma company Blueprint Medicines for $129 per share, making the deal worth more than $9 ...

Marc Frahm, an analyst at TD Cowen, downgraded Blueprint Medicines Corporation (NASDAQ:BPMC) from Buy to Hold. This ...

Wolfe Research downgraded Blueprint Medicines Corporation (NASDAQ:BPMC) to Peer Perform from Outperform without a price ...

Paris: Sanofi and Blueprint Medicines Corporation, a US-based, publicly traded biopharmaceutical company specializing in ...

Sanofi has agreed to purchase Blueprint Medicines for $129.00 per share in cash, valuing the deal at $9.1 billion, marking a 27.3% premium over Blueprint’s closing share price last Friday.

Sanofi and Blueprint Medicines Corporation have entered into an agreement under which Sanofi plans to acquire the US biopharmaceutical company Blueprint for 9.1 billion dollars.

We recently published a list of These 10 Stocks Blew Past Expectations. In this article, we are going to take a look at where ...

Sanofi to acquire US-based biopharma company, Blueprint Medicines for up to $9.5 billion: Paris Tuesday, June 3, 2025, 09:00 Hrs [IST] Sanofi and Blueprint Medicines Corporation ( ...